On behalf of the major subsidiary, Tanvex
Biologics Corporationto announce the change of
Accounting officer
Date of events
2022/08/19
To which item it meets
paragraph 8
Statement
1.Type of personnel changed (please enter: spokesperson, acting
spokesperson, important personnel (CEO, COO, CMO, CSO, etc.)
,financial officer, accounting officer, corporate governance officer,
chief information security officer, research and development officer,
chief internal auditor, or designated and non-designated representatives):
accounting officer
2.Date of occurrence of the change:2022/08/19
3.Name, title, and resume of the previous position holder:Hua-Chin Yen
4.Name, title, and resume of the new position holder:Jerry Yu
5.Type of the change (please enter: "resignation", "position
adjustment", "dismissal", "retirement", "death" or "new
replacement"):resignation
6.Reason for the change:resignation
7.Effective date:2022/08/19
8.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 19 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2022 11:43:07 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
